Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acumen Pharmaceuticals, Inc. filings document a clinical-stage biopharmaceutical issuer focused on Alzheimer’s disease programs targeting toxic soluble amyloid beta oligomers. Its Form 8-K reports include operating and financial results, business highlights, Regulation FD presentation updates, clinical and nonclinical program disclosures, and material agreements related to Enhanced Brain Delivery development.
Proxy materials describe annual meeting voting matters, board elections, auditor ratification, and equity incentive plan approvals. The filing record also discloses ABOS common stock registered on the Nasdaq Global Select Market, emerging growth company status, governance changes, capital-structure matters, and clinical and regulatory disclosure categories tied to drug development.
Acumen Pharmaceuticals director Nathan B. Fountain reported an open-market sale of 6,400 shares of Common Stock. The shares were sold on June 9, 2026 at a weighted average price of about $2.23 per share. After this transaction, he directly holds 48,150 shares of Acumen common stock.
Acumen Pharmaceuticals reported an equity compensation grant linked to director Dr. Laura Stoppel, as reflected on this Form 4 by RA Capital entities and related reporting persons. Dr. Stoppel received a restricted stock unit award covering 35,500 shares of common stock and a stock option for 53,250 shares with a $2.29 exercise price.
The RSUs and option will each vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, assuming Dr. Stoppel continues in service through that date. Under her arrangement with RA Capital Management, L.P., she holds these awards for the benefit of RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, and must deliver any net stock or cash received to the adviser to offset advisory fees. The reporting persons disclaim beneficial ownership of these awards and the underlying common stock beyond any pecuniary interest.
Acumen Pharmaceuticals director Nathan B. Fountain received new equity awards as part of his compensation. He was granted 35,500 shares of common stock in the form of restricted stock units, bringing his direct common stock holdings to 54,550 shares after the award. He also received stock options for 53,250 shares with an exercise price of $2.29 per share. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, provided he continues serving the company through that date.
Acumen Pharmaceuticals director Kimberlee C. Drapkin received new equity awards. She was granted 35,500 restricted stock units, each representing a right to receive one share of common stock. These RSUs vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to continued service.
She also received stock options covering 53,250 shares at an exercise price of $2.29 per share, expiring on June 3, 2036, with the same vesting schedule. Following these awards, she directly holds 48,300 shares of Acumen common stock. The transactions reflect compensation-related grants rather than open-market purchases or sales.
Acumen Pharmaceuticals director John A. Stalfort III received new equity awards. On June 3, 2026, he was granted 35,500 restricted stock units, each representing one share of common stock, and 53,250 stock options with an exercise price of $2.29 per share.
The RSUs and the option grant will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, as long as he continues to serve through that date. Following these awards, he directly holds 220,624 shares of common stock.
Acumen Pharmaceuticals director Derrell Porter received new equity awards. He was granted 35,500 restricted stock units, each representing one share of common stock, which will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to his continuous service.
Porter was also granted stock options for 53,250 shares of common stock at an exercise price of $2.29 per share, expiring on June 3, 2036, with the same vesting schedule. Following these grants, he directly holds 48,300 shares of common stock.
Acumen Pharmaceuticals director Jeffrey L. Ives received new equity awards as part of his compensation. He was granted 35,500 restricted stock units, each convertible into one share of common stock, and a stock option covering 53,250 shares at an exercise price of $2.29 per share.
The RSUs and the option will vest in full on the earlier of the first anniversary of the June 3, 2026 grant date or the company’s 2027 annual stockholder meeting, as long as he remains in continuous service. After the RSU grant, he directly holds 48,300 shares of common stock.
Acumen Pharmaceuticals director George Golumbeski received new equity compensation awards. He was granted 35,500 restricted stock units, each representing one share of common stock, and a stock option covering 53,250 shares at an exercise price of $2.29 per share.
The RSUs and the option will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, subject to his continuous service. After these grants, he directly holds 35,500 shares of common stock and 53,250 stock options from this award.
Stoppel Laura reported acquisition or exercise transactions in this Form 4 filing.
Acumen Pharmaceuticals director Laura Stoppel reported equity awards tied to RA Capital-managed vehicles. She was granted 35,500 restricted stock units (RSUs), each representing one share of common stock, and 53,250 stock options with a strike price of $2.29 per share.
The RSUs and options vest in full on the earlier of the first anniversary of the June 3, 2026 grant date or the 2027 annual stockholder meeting, subject to her continuous service. Under her arrangement with RA Capital Management, L.P., any shares or cash from these awards benefit RA Capital Healthcare Fund, RA Capital Nexus Fund II and a separately managed account, and she disclaims beneficial ownership of the underlying stock.